Back
Compare AU
Compare DRUG vs. VTS
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Global Healthcare Currency Hedged ETF (DRUG) and the Vanguard US Total Market Shares Index ETF (VTS). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | VTS | |
|---|---|---|
Popularity | Low | Medium |
Pearlers invested | 74 | 3,406 |
Median incremental investment | $740.50 | $1,300.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,755.07 | $5,272.08 |
Average age group | 26 - 35 | > 35 |
Key Summary
DRUG | VTS | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | Vanguard U.S. Total Market Shares Index ETF (ASX: VTS) seeks to track the performance of the CRSP US Total Market Index before account fees, expenses and taxes. The index tracks the large, mid, small and micro-cap stocks on the US stock market, thus representing nearly 100% of the investable US stock market. |
Top 3 holdings | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) | Apple Inc. (5.56 %) Microsoft Corp. (4.68 %) Amazon.com Inc. (2.06 %) |
Top 3 industries | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) | Information Technology (25.02 %) Health Care (15.04 %) Financials (10.84 %) |
Top 3 countries | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) | United States (99.42 %) Switzerland (0.22 %) Canada (0.10 %) |
Management fee | 0.57 % | 0.03 % |
Key Summary
DRUG | VTS | |
|---|---|---|
Issuer | BetaShares | Vanguard |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | CRSP U.S. Total Market Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.03 % |
Price | $8.71 | $479.28 |
Size | $176.672 million | $586.721 billion |
10Y return | N/A | 249.69 % |
Annual distribution yield (5Y) | 1.92 % | 1.17 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 08/05/2009 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | VTS | |
|---|---|---|
Popularity | Low | Medium |
Pearlers invested | 74 | 3,406 |
Median incremental investment | $740.50 | $1,300.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,755.07 | $5,272.08 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
DRUG | VTS | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | VTS |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |